Compare Abeona Therapeutics Inc (ABEO) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs VanEck Australian Floating Rate ETF — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while VanEck Australian Floating Rate ETF trades at $50.97. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | FLOT | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Sector/Thematic |
52-Week High | $7.23 | $51.09 |
52-Week Low | $4.17 | $50.72 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
FLOT trades at $50.96, up 0.08% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, and recent dividends include $0.18 paid in June 2026. News highlights potential Fed rate hikes as a catalyst for yield growth, while credit quality remains strong with minimal default risk.
Outlook is cautious due to bearish technicals and interest rate uncertainty, but FLOT provides a stable income stream with low credit risk. Key risks include inflation-driven rate volatility and economic shifts affecting bond yields, making it suitable for investors seeking short-term cash parking with modest returns above Treasuries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →
